Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Yale University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03359174CT.gov An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis | — | Terminated | — | — | — |
NCT01456468CT.gov Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Sclerosing Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tretinoin (this asset) | Yale University | P2 | B · 60 |
| Vancomycin | Tampere University Hospital | P4 | BB |
| Ursodeoxycholic Acid | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Aldafermin | NGM Biopharmaceuticals, Inc | P2/3 | B |
| Elafibranor | Ipsen | P3 | B |
| CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY | ChemomAb Ltd. | P2 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
| Cilofexor | Gilead Sciences | P3 | B |
| cs0159 | Cascade Pharmaceuticals, Inc | P2 | B |
+42 more in the Primary Sclerosing Cholangitis cohort
Other indications for Tretinoin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P3 | BB · 69 |
| Acute Myeloid Leukemia | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tretinoin in Primary Sclerosing Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tretinoin-primary-sclerosing-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →